Literature DB >> 16813906

Determining the importance of change in the overactive bladder questionnaire.

Karin S Coyne1, Louis S Matza, Christine L Thompson, Zoe S Kopp, Vikram Khullar.   

Abstract

PURPOSE: The overactive bladder questionnaire assesses symptom bother and health related quality of life in patients with overactive bladder. It has been shown to be reliable, valid and responsive. We established the minimally important difference of the overactive bladder questionnaire.
MATERIALS AND METHODS: Post hoc analyses from 2 clinical trials were performed. Distribution based, eg effect size, and anchor based analyses using perception of treatment benefit and clinical variables were used.
RESULTS: The mean age of the 2 study populations was 58.8 and 58.7 years, respectively. Patients were predominantly female (51.8% and 75.1%) and white (83.9% and 87%, respectively). Half SD of the overactive bladder questionnaire symptom bother subscale was 9.1 to 9.3, and half SD of the overactive bladder questionnaire health related quality of life subscales (coping, concern, sleep and social interaction) was 9.8 to 13.2. Questionnaire subscales had moderate to large effect sizes with the largest effect sizes for symptom bother (-0.85 to -1.09). Anchor based analyses showed that significantly greater change scores were associated with greater patient perceived treatment benefit and satisfaction. The difference between change scores in patients perceiving no and little benefit was 7.4 to 16.5 for all questionnaire scales except social interaction with the majority greater than 10 points. Greater change scores were consistently associated with greater improvements in micturition diary variables.
CONCLUSIONS: Multiple methodologies provide strong justification for the recommendation of a 10-point minimally important difference for all overactive bladder questionnaire subscales. This minimally important difference may be conservative for some subscales, although a uniform minimally important difference is recommended to facilitate interpretation of the overactive bladder questionnaire.

Entities:  

Mesh:

Year:  2006        PMID: 16813906     DOI: 10.1016/j.juro.2006.03.088

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  34 in total

Review 1.  A systematic review of English language patient-reported outcome measures for use in urogynaecology and female pelvic medicine.

Authors:  Thomas G Gray; Holly Vickers; Priyanka Krishnaswamy; Swati Jha
Journal:  Int Urogynecol J       Date:  2021-05-26       Impact factor: 2.894

2.  Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

Authors:  Jörg Witthaut; Andrew G Bushmakin; Robert A Gerber; Joseph C Cappelleri; Marie-Pierre Hellio Le Graverand-Gastineau
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

3.  Clinically meaningful improvement on the Self-Esteem And Relationship questionnaire in men with erectile dysfunction.

Authors:  Joseph C Cappelleri; Stanley E Althof; Michael P O'Leary; Sidney Glina; Rosie King; Vera J Stecher; Martin Carlsson; Richard L Siegel
Journal:  Qual Life Res       Date:  2007-07-07       Impact factor: 4.147

Review 4.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

5.  Minimum important difference for validated instruments in women with urge incontinence.

Authors:  Keisha Y Dyer; Yan Xu; Linda Brubaker; Ingrid Nygaard; Alayne Markland; David Rahn; Toby C Chai; Ann Stoddard; Emily Lukacz
Journal:  Neurourol Urodyn       Date:  2011-05-11       Impact factor: 2.696

6.  The minimum important difference for the Pelvic Organ Prolapse-Urinary Incontinence Sexual Function Questionnaire.

Authors:  M M Mamik; R G Rogers; C R Qualls; J D Morrow
Journal:  Int Urogynecol J       Date:  2014-02-22       Impact factor: 2.894

7.  Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Authors:  Salvador Arlandis; Miguel A Ruiz; Carlos Errando; Felipe Villacampa; Daniel Arumí; Isabel Lizarraga; Javier Rejas
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

8.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

9.  Does concomitant anterior/apical repair during midurethral sling improve the overactive bladder component of mixed incontinence?

Authors:  Alexis A Dieter; Autumn L Edenfield; Alison C Weidner; Pamela J Levin; Nazema Y Siddiqui
Journal:  Int Urogynecol J       Date:  2014-05-09       Impact factor: 2.894

10.  Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.

Authors:  Jeffrey P Weiss; Zhanna Jumadilova; Theodore M Johnson; Mary P Fitzgerald; Martin Carlsson; Diane L Martire; Atul Malhotra
Journal:  J Urol       Date:  2012-11-15       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.